Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 651 - 675 of 15379 in total

Viltolarsen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … Although corticosteroids are effective in slowing disease progression in both DMD and BMD patients, they ... [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... mutations allows for exon skipping, which retains a productive reading frame and results in the production …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Tovorafenib

Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation ... growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell …

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … used neuromuscular blocking agents in intensive care. ... [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in …

Lasofoxifene

Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as...
Approved
Investigational
Matched Description: … commercialization of oral lasofoxifene in the USA. ... with a newly submitted New Drug Application in 2008. ... It gained approval by European Commission in March 2009. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …

Relebactam

Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Matched Description: … [A181207] It is currently available in a combination product which includes [imipenem] and [cilastatin ... infections in adults. ... product RecarbrioⓇ in July 2019. …
Matched Categories: … imipenem, cilastatin and relebactam …

Imipenem

Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ertapenem which exhibits...
Approved
Matched Description: … [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug ... Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed ... gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. …
Matched Mixtures name: … Imipenem and Cilastatin ... Imipenem and Cilastatin ... Imipenem and Cilastatin …
Matched Categories: … imipenem and cilastatin ... imipenem, cilastatin and relebactam …

Terlipressin

Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been...
Approved
Investigational
Matched Description: … [L43217] As a potent vasopressor, terlipressin has been investigated in various shock states and conditions ... [A2601, A2602, A2603, A2604, A2605] It was also studied in hepatorenal syndrome (HRS) and variceal bleeding ... [A252672] The drug was first approved by the FDA in September 2022.[L43217] …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Vasopressin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Cipaglucosidase alfa

Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … types of enzyme replacement therapy for the treatment of Pompe disease include [alglucosidase alfa] and ... cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease,[L45275] and ... skeletal muscle, one of the main affected tissues in Pompe disease. …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Sevoflurane

Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996....
Approved
Vet approved
Matched Description: … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved ... [A249910] Therefore, it can be used for inhalational induction in adults and children for a wide variety ... by the FDA in 1996. …

Faricimab

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced NV ... depleting VEGF-A and Ang-2, which has been developed to improve therapeutic efficacy, especially in ... [L40026] It received subsequent approval for the same indications in Canada in May 2022. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Cilgavimab

SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [L41549] In October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing ... in Canada soon after, on April 14, 2022. ... Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Tixagevimab

SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [L41549] In October 2022, the FDA and Health Canada released safety alerts regarding the risk of ... in Canada soon after, on April 14, 2022. ... Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Chlorphenesin

Approved
Experimental

Sulconazole

Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial ... Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and ... inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and …
Matched Categories: … Imidazole and Triazole Derivatives …

Imatinib

Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". ... [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA ... ; however, its European approval has been withdrawn in October 2023. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Ketoconazole

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation...
Approved
Investigational
Matched Description: … Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal ... Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations. ... [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in …
Matched Categories: … Sex Hormones and Insulins ... Imidazole and Triazole Derivatives ... Gynecological Antiinfectives and Antiseptics ... Metabolic Side Effects of Drugs and Substances …

Pyrantel

Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis . Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Description: … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% ... Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and ... infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and …
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …

Remoxipride

Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Description: … [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated …
Matched Categories: … Benzamides and benzamide derivatives …

Diroximel fumarate

Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Description: … in October 2019[L9626] and by the EMA in November 2021. ... Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA ... of both North America and Europe. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Calcitriol

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to DB00169 (vitamin D3)...
Approved
Nutraceutical
Matched Description: … to [DB00146] in the liver and kidneys. ... Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate [A26353 ... Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of …
Matched Categories: … Alimentary Tract and Metabolism ... Vitamin D and Analogues ... Diet, Food, and Nutrition ... Skin and Mucous Membrane Agents ... Calcium-Regulating Hormones and Agents …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell ... ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Flavin mononucleotide

A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.
Approved
Investigational
Matched Description: … It is the principal form in which RIBOFLAVIN is found in cells and tissues. …
Matched Mixtures name: … Multi Vitamin and Fluoride ... Somarexin and C 1000 ... Multi Vitamin and Fluoride …
Matched Categories: … Enzymes and Coenzymes ... Nucleic Acids, Nucleotides, and Nucleosides …

Eflornithine

Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA ... the risk of relapse and a 68% reduction in the risk of death were observed. ... hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells. …
Matched Categories: … Skin and Mucous Membrane Agents ... Amino Acids, Peptides, and Proteins ... Agents Against Leishmaniasis and Trypanosomiasis ... Antineoplastic and Immunomodulating Agents ... Antiparasitic Products, Insecticides and Repellents …

Nisoldipine

Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Description: … muscle contraction and subsequent vasoconstriction. ... Nisoldipine may be used in alone or in combination with other agents in the management of hypertension ... acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Telmisartan

Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to...
Approved
Investigational
Matched Description: … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. ... inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in …
Matched Mixtures name: … Telmisartan and Amlodipine ... Telmisartan and Amlodipine ... Telmisartan and Amlodipine …
Matched Categories: … telmisartan and diuretics ... telmisartan and amlodipine ... rosuvastatin and telmisartan ... telmisartan, amlodipine and hydrochlorothiazide ... Angiotensin II receptor blockers (ARBs) and diuretics …
Displaying drugs 651 - 675 of 15379 in total